My Way

Low folate status contributes to elevated homocysteine, a metabolite that has been associated with endothelial dysfunction, arterial stiffness, and a higher risk of stroke and coronary heart disease. Large observational studies consistently show that individuals with higher homocysteine levels have greater rates of cardiovascular events, and folate intake is one of the key nutritional determinants of homocysteine. Clinically, folic acid supplementation (often combined with vitamins B6 and B12) can lower homocysteine and appears to modestly reduce stroke risk in some populations, making the identification and correction of folate deficiency an important part of broader cardiovascular risk reduction.

Folate deficiency in the periconceptional period significantly increases the risk of neural tube defects (NTDs) such as spina bifida and anencephaly, because adequate folate is required for proper closure of the embryonic neural tube in the first month of pregnancy. Large observational datasets and randomized trials have shown that appropriate folic acid supplementation before conception and in early pregnancy can reduce NTD risk by roughly 50–70% in the general population, with even greater risk reduction in women with a prior NTD‑affected pregnancy. The practical implication is that all women of childbearing potential, not just those actively planning pregnancy, are typically advised to maintain adequate daily folic acid intake so that red‑cell folate stores are sufficient well before conception occurs.

In susceptible adults, acute thiamine (vitamin B1) deficiency can rapidly trigger an encephalopathy marked by confusion, gait ataxia, and ocular motor abnormalities such as nystagmus or ophthalmoplegia. This classic triad is often incomplete at presentation, and only a minority of patients show all three features together initially, which contributes to delayed diagnosis. Because body stores are quickly exhausted, maintaining adequate ongoing thiamine intake is critical, and can reverse many of the acute neurologic signs if started early, whereas even short delays increase the risk of persistent cognitive impairment and structural brain injury on imaging.

Low zinc status has been linked to a higher risk and faster progression of age-related macular degeneration (AMD), in part because zinc is concentrated in the retina and supports antioxidant defenses there. In the landmark AREDS trial, a supplement formula containing zinc (80 mg as zinc oxide), along with antioxidants, reduced the risk of progression to advanced AMD by about 25% in people with intermediate disease or advanced disease in one eye over roughly 5 years. Other research has shown that inadequate zinc intake is more common in older adults with AMD, reinforcing the idea that maintaining healthy zinc levels may be an important, and often overlooked, strategy for preserving macular health with age.

In older adults, low folate status has been associated with a higher risk of mild cognitive impairment (MCI) and faster cognitive decline over time, likely through effects on one‑carbon metabolism and homocysteine. Several longitudinal cohort studies have found that individuals with lower serum or red‑cell folate and higher homocysteine show steeper declines on memory and global cognition tests, and in some cohorts have a significantly higher incidence of MCI or dementia over follow‑up. The clinically important takeaway is that, when folate deficiency is detected and corrected (usually along with ensuring adequate vitamin B12), some patients demonstrate stabilization or modest improvement in cognitive performance, particularly when interventions are combined with aggressive management of vascular risk factors such as hypertension and diabetes.

In both children and adults, vitamin E deficiency can contribute to retinopathy and visual impairment because α‑tocopherol serves as a key fat‑soluble antioxidant that protects photoreceptor cells and retinal membranes from cumulative oxidative damage. Clinical reports describe patients with prolonged low vitamin E status developing pigmentary retinopathy, reduced visual acuity, and abnormal electroretinograms, sometimes alongside peripheral neuropathy, which can improve partially when deficiency is identified and corrected. These neurosensory changes appear more frequently in settings of fat malabsorption or genetic disorders affecting vitamin E transport, highlighting the importance of monitoring vitamin E status in at‑risk groups with otherwise unexplained visual decline.